Company: MDCXW
Filing Date: 2025-12-08
Form Type: 253G2
Source: 0001062993-25-017235
Chunk: 1

Company: Medicus Pharma Ltd.
Filing Date: 2025-12-08
Form: 253G2
Chunk 1
---
 or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this offering circular supplement is December 8, 2025.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)</div>

| Ontario                      | 001-42408    | 98-1778211          |
| (State or other jurisdiction | (Commission  | (IRS Employer       |
| of incorporation)            | File Number) | Identification No.) |

<div align='center'>300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515</div>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                     |     | Trading Symbols |     | Name of each exchange on which registered |
| Common shares, no par value                                                             |     | MDCX            |     | NASDAQ Capital Market                     |
| Warrants, each exercisable for one common share at an exercise price of $4.64 per share |     | MDCXW           |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405